FILOCLL017 - NEVOTAL : Nemtabrutinib in addition to Venetoclax-Obinutuzumab in chronic lymphocytic leukemia (CLL) / small lymphocytic leukemia (SLL) patients with TP53 ALterations
Chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) are slow-growing types of blood cancer. In some people, the cancer cells have a specific gene change called a TP53 alteration, which can make the condition harder to treat with usual medicines. This clinical trial is testing whether adding a new targeted drug called nemtabrutinib to two established treatments—venetoclax (tablets) and obinutuzumab (given through a drip)—is safe and effective. The goal is to see if this combination can clear cancer cells so deeply that doctors cannot detect any remaining leukaemia in the bone marrow using sensitive tests. Participants receive treatment in cycles over about 15 to 16 months. Doctors will monitor how well the cancer responds, track side effects, and check blood counts regularly. This trial aims to find more effective, longer-lasting treatment options for people with this specific type of leukaemia.
At a glance
What is this study about?
Chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) are blood conditions where the body makes too many abnormal white blood cells. Sometimes, testing shows a change in a gene called TP53. When this gene is altered, cancer cells often do not respond as well to standard treatments, and doctors need different ways to tackle the disease.
This study tests a treatment plan made up of three medicines. Two of them—obinutuzumab (a drip medicine) and venetoclax (a daily tablet)—are already used to treat leukaemia. The third medicine, nemtabrutinib, is an experimental tablet designed to block specific signals that leukaemia cells need to grow and survive. Researchers want to find out whether combining all three works better than standard care.
The main aim of the trial is to see if the combination can lead to what doctors call 'undetectable minimal residual disease'. This means the treatment has cleared away so many leukaemia cells that specialised lab tests cannot find any in the bone marrow. Achieving this deep response often gives people a longer break before their cancer shows any sign of returning.
Because this is a phase 2 study, the trial team will also keep a very close eye on safety. They will track changes in healthy blood cells and record any side effects. The results will help doctors understand whether this combination could become a valuable new treatment option for people facing hard-to-treat leukaemia.
Key takeaways
- Tests a new triple-drug combination for adults with CLL or SLL who have a TP53 gene alteration.
- Combines a new targeted tablet (nemtabrutinib) with two existing treatments (venetoclax and obinutuzumab).
- Aims to clear leukaemia cells deeply from the bone marrow to give people longer lasting remissions.
- Treatment lasts around 15 to 16 months and includes clinic visits, blood tests, and scans.
- Participation is entirely voluntary, and your safety is closely monitored throughout.
Who may be eligible?
This trial is for adults aged 18 or older who have been diagnosed with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). To be suitable, tests must confirm that your leukaemia cells carry a specific genetic change known as a TP53 alteration.
You will need to be well enough to manage daily activities and have reasonably healthy liver, kidney, and heart function. Your medical team will run blood and general health tests to check if joining is safe for you.
You may not be able to take part if you have severe active infections, significant uncontrolled health problems, or if you are pregnant or breastfeeding. Your hospital doctor will review your full medical history and current medications to see if this trial is a good match.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have been diagnosed with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).
- Testing has shown my cancer cells have a TP53 gene alteration.
- I am well enough to attend regular hospital appointments and take daily tablets.
- I do not have a severe active infection or serious uncontrolled medical condition.
What does participation involve?
Taking part involves receiving three medicines on a set schedule of treatment cycles over roughly 15 to 16 months. Obinutuzumab is given as a drip into a vein at the hospital for the first 6 cycles. Venetoclax and nemtabrutinib are tablets that you swallow at home once a day for up to 12 and 15 cycles, respectively.
You will need to visit the hospital clinic regularly for health check-ups, especially during the early weeks when your doses are starting. At these visits, the team will check your blood pressure, test your blood, ask about side effects, and perform physical checks.
To see how well the treatment is working, you will have imaging scans and bone marrow samples taken at specific points during the study. After completing the active treatment, you will continue to have routine follow-up visits so doctors can monitor your long-term health and see how long the treatment benefits last.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What is a TP53 alteration?
TP53 is a gene that normally acts like a brake to stop damaged cells from growing. If it is altered or missing in leukaemia cells, the cancer can be more resistant to standard treatments, so doctors look for newer targeted therapies.
Will I have to stay overnight in the hospital?
Most visits are day appointments for clinic checks, blood tests, or drip treatments. You usually go home the same day, although an overnight stay might be needed occasionally if you need extra monitoring during your first infusions.
What happens if I experience side effects?
Your care team will monitor you closely at every visit. If side effects occur, doctors can prescribe supportive medicines, lower your dose, or temporarily pause treatment until you feel better.
Can I leave the study if I change my mind?
Yes. You have the right to withdraw from the trial at any point, for any reason. Deciding to leave will not affect your relationship with your medical team or the standard of care you receive.
Do I have to pay for the trial medicines?
No. The trial medicines and any extra study tests are provided free of charge. Travel costs to attend extra hospital appointments may also be reimbursed depending on the trial centre.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.